Aerovate Therapeutics
Aerovate Therapeutics Logo
About Aerovate Therapeutics
Aerovate Therapeutics Inc is a clinical-stage biotechnology company focused on developing novel therapies for rare cardiopulmonary diseases. Its lead program, AV-101, is a proprietary dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company is dedicated to advancing innovative treatments that address the underlying drivers of disease and improve the lives of patients with debilitating cardiopulmonary conditions in the United States.
Address
930 Winter Street, Suite M-500
Waltham, 02451
United States
Year founded
2018
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
